Search results
Results from the WOW.Com Content Network
Midodrine, also known as 3,6-dimethoxy-β-hydroxy-N-aminoethanonyl-2-phenylethylamine, is a substituted phenethylamine derivative. [4] Midodrine is an odorless, white, crystalline powder, soluble in water and sparingly soluble in methanol. [19] Midodrine's experimental log P is -0.5 and its predicted log P ranges from -0.49 to -0.95.
A systematic review and meta-analysis conducted on clinical trials comparing the clinical use of droxidopa and midodrine have found that midodrine was more likely to cause supine hypertension than droxidopa in patients with NOH. Midodrine was also found to be slightly more effective at raising blood pressure but not statistically significantly ...
Desglymidodrine (developmental code name ST-1059) is the active metabolite of the prodrug antihypotensive agent midodrine. [1] [2] [3] It acts as a selective α 1-adrenergic receptor agonist. [1] [2] [3] Desglymidodrine is formed from midodrine via deglycination. [1] [2] [3]
Ionizing radiation may be used to treat other cancers, but this may, in some cases, induce a second form of cancer. [74] Radiation can cause cancer in most parts of the body, in all animals, and at any age, although radiation-induced solid tumors usually take 10–15 years, and can take up to 40 years, to become clinically manifest, and ...
Cancer Causes & Control is a peer-reviewed medical journal published by Springer Science+Business Media, covering research on the epidemiology, causes, and control of cancer. According to the Journal Citation Reports , the journal has a 2020 impact factor of 2.506.
Scientist Otto Warburg, whose research activities led to the formulation of the Warburg hypothesis for explaining the root cause of cancer.. The Warburg hypothesis (/ ˈ v ɑːr b ʊər ɡ /), sometimes known as the Warburg theory of cancer, postulates that the driver of carcinogenesis (cancer formation) is insufficient cellular respiration caused by insult (damage) to mitochondria. [1]
Breast cancer survivors Michele Young, a Cincinnati attorney, and Kristen Dahlgren, an award-winning journalist, are launching a nonprofit they believe could end breast cancer, once and for all.
The organization initiated Know Your Tumor in 2014, a precision medicine service that uses molecular profiling to give doctors and their patients details about the biology of their tumor to help with treatment choices. [10] In 2015, they launched the Clinical Trial Finder online resource with a directory of U.S. pancreatic cancer clinical ...